Global Health Data Exchange - Discover the World's Health Data

Seroprevalence of SARS-CoV-2 in the Norwegian population measured in residual sera collected in April/May 2020 and August 2019


General Info
Norway (NOR)
Coverage type 
Time period covered 
08/2019 - 05/2020
Series or system 
Norwegian Influenza Study (NorFlu)
Data type

A total of 900 residual sera from nine laboratories were sampled in week numbers 17-20, 2020, and tested for antibodies against SARS-CoV-2 using a novel in-house assay established at the Department of Immunology, Oslo University Hospital. Based on these measurements, the estimated seroprevalence in the Norwegian population is probably close to 1% (1.0% (95% credible interval 0.1% -2.4%)).